{"id":89757,"date":"2025-10-20T11:20:03","date_gmt":"2025-10-20T09:20:03","guid":{"rendered":"https:\/\/port.lukasiewicz.gov.pl\/?post_type=projects&p=89757"},"modified":"2025-12-19T09:45:46","modified_gmt":"2025-12-19T08:45:46","slug":"optimization-of-the-production-and-purification-of-virus-like-particles-vlps-presenting-the-her2-antigen-as-a-therapeutic-vaccine-candidate-against-breast-cancer-process-scaling-and-preclinical-pro","status":"publish","type":"projects","link":"https:\/\/port.lukasiewicz.gov.pl\/en\/projekty-badawcze\/optimization-of-the-production-and-purification-of-virus-like-particles-vlps-presenting-the-her2-antigen-as-a-therapeutic-vaccine-candidate-against-breast-cancer-process-scaling-and-preclinical-pro\/","title":{"rendered":"Optimization of the Production and Purification of Virus-Like Particles (VLPs) Presenting the HER2 Antigen as a Therapeutic Vaccine Candidate Against Breast Cancer: Process Scaling and Preclinical Product Characterization \u2013 AHER2VAC8"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Contract No.: 2024\/ABM\/05\/KPO\/KPOD.07.07-IW.07-0269\/24-00<\/strong>
Project value: PLN 5,533,491.42<\/strong>
Funding amount: PLN 4,650,365.92<\/strong>
Funding for \u0141ukasiewicz \u2013 PORT: PLN 1,117,863.94<\/strong>
Project duration: 03\/02\/2025 \u2013 31\/02\/2026<\/strong>
Project Manager: \u0141ukasz R\u0105balski (Vaxican)<\/strong>
R&D Project Manager: PhD Tomasz Lipi\u0144ski (\u0141ukasiewicz \u2013 PORT)<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tVIEW PROJECT<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Project implemented in Consortium:<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

  1. VAXiCAN Sp. z o.o. (Gda\u0144sk)<\/strong> \u2013 Leader<\/p><\/li>

  2. \u0141ukasiewicz Research Network \u2013 PORT Polish Center for Technology Development<\/strong><\/p><\/li><\/ol>

    The aim of the project is to optimize the production and purification of virus-like particles (VLPs)<\/strong> presenting the HER2 antigen<\/strong> as a candidate for a therapeutic vaccine<\/strong> against HER2-positive breast cancer<\/strong>. The project is based on an innovative platform utilizing virus-like particles derived from avian paramyxovirus serotype 1 (PPMV-1)<\/strong> presenting the extracellular domain of the HER2 receptor<\/strong>.<\/p>

    HER2 (human epidermal growth factor receptor 2)<\/strong> is a key therapeutic target in breast cancer due to its overexpression in approximately 20\u201330% of cases. HER2-positive tumors are particularly aggressive and associated with poorer prognosis. Our innovative VLP platform<\/strong> has the potential to present the HER2 antigen to the immune system, leading to the activation of both cellular and humoral immunity<\/strong>, resulting in a more effective and safer immunotherapy<\/strong> compared to monoclonal antibody treatments.<\/p>

    Within the project, we plan to:<\/p>

    • prepare several variants of the active molecule,<\/p><\/li>

    • conduct studies to select the most promising variant,<\/p><\/li>

    • scale up the production process,<\/p><\/li>

    • develop the purification technology, and<\/p><\/li>

    • perform partial preclinical characterization<\/strong> of the product.<\/p><\/li><\/ul>

      The selected vaccine candidate will be secured for further research, including future clinical studies<\/strong>. The next-generation immunotherapeutic being developed will feature a set of unique properties: high antigen expression, optimal antibody generation, ease and low cost of production, low toxicity and fewer side effects, and the potential to provide long-term protection.<\/strong><\/p>

      The project will bring significant benefits to the Polish biotechnology sector<\/strong>, strengthening the country\u2019s position as a hub of innovation in the field of biomedicine<\/strong>. It will enhance the potential for similar projects in the future and promote the application of research results within the healthcare system<\/strong>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

      Contract No.: 2024\/ABM\/05\/KPO\/KPOD.07.07-IW.07-0269\/24-00Project value: PLN 5,533,491.42Funding amount: PLN 4,650,365.92Funding for \u0141ukasiewicz \u2013 PORT: PLN 1,117,863.94Project duration: 03\/02\/2025 \u2013 31\/02\/2026Project Manager: \u0141ukasz R\u0105balski (Vaxican)R&D Project Manager: PhD Tomasz Lipi\u0144ski (\u0141ukasiewicz \u2013 PORT) VIEW PROJECT Project implemented in Consortium: VAXiCAN Sp. z o.o. (Gda\u0144sk) \u2013 Leader \u0141ukasiewicz Research Network \u2013 PORT Polish Center for Technology Development The […]<\/p>\n","protected":false},"featured_media":76193,"menu_order":0,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","inline_featured_image":false,"footnotes":""},"categories":[595],"grupy_badawcze":[609],"pozostale_projekty":[],"class_list":["post-89757","projects","type-projects","status-publish","format-standard","has-post-thumbnail","hentry","category-zakonczone","grupy_badawcze-grupa-badawcza-bioinznierii"],"acf":{"order":"0","kierownik_projektu":["Dr. Tomasz Lipi\u0144ski"],"dofinansowanie":"Agencja Bada\u0144 Medycznych","grupa_badawcza":["Bioengineering Research Group"],"nazwa_projektu":"","tematyka_projektu":"","opis_projektu":"","dofinanowanie":"Medical Research Agency"},"publishpress_future_action":{"enabled":false,"date":"2026-05-07 10:18:22","action":"category","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/projects\/89757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/projects"}],"about":[{"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/types\/projects"}],"version-history":[{"count":5,"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/projects\/89757\/revisions"}],"predecessor-version":[{"id":96639,"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/projects\/89757\/revisions\/96639"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/media\/76193"}],"wp:attachment":[{"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/media?parent=89757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/categories?post=89757"},{"taxonomy":"grupy_badawcze","embeddable":true,"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/grupy_badawcze?post=89757"},{"taxonomy":"pozostale_projekty","embeddable":true,"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/pozostale_projekty?post=89757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}